Q1 2016 13F Holders as of 3/31/2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
24
-
Total 13F shares, excl. options
-
5.69M
-
Shares change
-
-68.1K
-
Total reported value, excl. options
-
$39.8M
-
Value change
-
-$1.43M
-
Number of buys
-
8
-
Number of sells
-
-7
-
Price
-
$6.99
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q1 2016
25 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q1 2016.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 24 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.69M shares
of 77.3M outstanding shares and own 7.36% of the company stock.
Largest 10 shareholders include BVF INC/IL (1.78M shares), Capital World Investors (1.03M shares), ROYAL BANK OF CANADA (468K shares), Invesco Private Capital, Inc. (436K shares), Visium Asset Management, LP (420K shares), Opaleye Management Inc. (400K shares), Point72 Asset Management, L.P. (359K shares), PERCEPTIVE ADVISORS LLC (206K shares), DAFNA Capital Management LLC (193K shares), and Novo A/S (128K shares).
This table shows the top 24 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.